Docetaxel

127 trials 59 recruiting LOncology

Filter these 127 trials by condition, phase, country and more.

Open in Search →

127 Registered trials

59 Recruiting

59 Completed trials

75 Sponsors

26 Countries

Phase III

Phase II

Phase III: 63 Phase II/III: 5 Phase II: 44 Phase I/II: 7 Phase IV: 6 Phase I (FiH): 2

Oversight events:

3 serious breaches 24 temporary halts 2 urgent safety measures 3 unexpected events 2 corrective measures across 14 trials

View oversight register →

Indications tested

Non-small cell lung cancer 16 Non-small cell lung cancer metastatic 6 Prostate cancer metastatic 6 Breast cancer 3 Gastrooesophageal cancer 3 Non-small cell lung cancer stage III 2 Adenocarcinoma gastric 2 Endometrial cancer 2 HER2 positive breast cancer 2 Breast cancer female 2 Prostate cancer 2 Breast cancer stage III 2

Sponsors using this IMP

Merck Sharp & Dohme LLC 16 AstraZeneca AB 7 Unicancer 4 Bristol-Myers Squibb Services Unlimited Company 3 Daiichi Sankyo Inc. 3 F. Hoffmann-La Roche AG 3 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 3 Gilead Sciences Inc. 3 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 3 Intergroupe Francophone De Cancerologie Thoracique 3 Karolinska University Hospital 3 AbbVie Deutschland GmbH & Co. KG 2

All trials — page 6

127 total

A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lu… Ended

2023-504038-23-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Urothelial Cancer Ended

2023-510296-56-00 Phase III 3 countries Janssen Cilag International
Perioperative treatment of locally advanced resectable gastric or GEJ adenocarcinoma Ended

2023-509595-42-00 Phase III 8 countries Merck Sharp & Dohme LLC
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic cas… Ended

2024-511660-89-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung… Ended

2022-501360-18-00 Phase III 4 countries Bristol-Myers Squibb International Corporation
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati… Ended

2023-509227-41-00 Phase II 1 country Centre Leon Berard
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative settin… Ended

2024-514078-29-00 Phase II 1 country Institut De Cancerologie De L Ouest

Showing 121–127 of 127 trials

← All drugs A–Z